These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37942955)

  • 21. Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation.
    Grossi PA; Kamar N; Saliba F; Baldanti F; Aguado JM; Gottlieb J; Banas B; Potena L
    Transpl Int; 2022; 35():10332. PubMed ID: 35812158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
    Koval CE
    Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones CJ; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R; Mariette C; Alain S; Lupo J; Thiebaut A; Brion JP; Epaulard O; Saint Raymond C; Malvezzi P; Morand P
    Antiviral Res; 2014 Jan; 101():57-61. PubMed ID: 24184983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation.
    Pérez A-B; Santos Bravo M; Vidal-Verdú E; Páez-Vega A; Vaquero-Barrios J-M; Montero J-L; Marcos M-Á; Torre-Cisneros J
    Microbiol Spectr; 2023 Dec; 11(6):e0163023. PubMed ID: 37902387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future options for cytomegalovirus reactivation in hematopoietic cell transplantation patients.
    Maertens J; Lyon S
    Future Microbiol; 2017 Aug; 12():839-842. PubMed ID: 28745073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants).
    Cochran WV; Dioverti MV; Langlee J; Barker LN; Shedeck A; Toman LP; Avery RK
    Ann Transplant; 2024 Apr; 29():e941185. PubMed ID: 38650316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
    Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.
    Sia IG; Patel R
    Clin Microbiol Rev; 2000 Jan; 13(1):83-121, table of contents. PubMed ID: 10627493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
    Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
    J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
    Meesing A; Razonable RR
    Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants.
    Allaw F; Haddad SF; Zakhour J; Kanj SS
    Int J Antimicrob Agents; 2023 Aug; 62(2):106860. PubMed ID: 37220849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
    Bueno J; Ramil C; Green M
    Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
    Benmarzouk-Hidalgo OJ; Cordero E; Martín-Peña A; García-Prado E; Gentil MA; Gomez-Bravo MA; Barrera-Pulido L; Cisneros JM; Perez-Romero P
    Antivir Ther; 2009; 14(5):641-7. PubMed ID: 19704166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.